Expression of metalloproteinases endometrial stromal sarcoma: Immunohistochemical study using image analysis

Journal of Clinical Pathology

Volumn 52, Issue 3, 1999, Pages 198-202

  Liokumovich, Pavel ^c   Goldberg, Iris ^c   Davidson, Ben ^b   Gotlieb, Walter H ^c   Zahavi, Thomas ^a   Ben Baruch, Gilad ^c   Reder, Ilan ^c   Kopolovic, Juri ^c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NONE

Author keywords

Endometrial stromal sarcoma; Gelatinases; Image analysis; Metalloproteinases; Stromelysins

Indexed keywords

GELATINASE; METALLOPROTEINASE; STROMELYSIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; CELL DIFFERENTIATION; CLINICAL ARTICLE; ENDOMETRIUM SARCOMA; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN DEGRADATION; STROMA CELL; TUMOR LOCALIZATION;

EID: 0032981694     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.52.3.198     Document Type: Article

References (38)

1. 1 Hendrickson MR, Kempson RL. Pure mesenchymal neoplasms of the uterine corpus. In: Fox H, ed. Haines and Taylor: obstetrical and gynaecological pathology, vol 1. London: Churchill Livingstone, 1995:519-86.
2. 2 Farhood AI, Abrams J. Immunohistochemistry of endometrial stromal sarcoma. Hum Pathol 1991;22:224-30.
3. 3 Lillemoe TJ, Perrone T, Norris HJ, et al. Myogenous phenotype and epithelial-like areas in endometrial stromal sarcomas. Arch Pathol Lab Med 1991;115:215-19.
4. 4 Tosi P, Sforza V, Santopietro R. Estrogen receptor content, immunohistochemically determined by monoclonal antibodies, in endometrial stromal sarcoma. Obstet Gynecol 1989;73:75-8.
5. 5 Dabbs DJ, Silverman JF, Geisinger KR. Immunohistochemical study of uterine stromal sarcoma and rhabdomyosarcoma. Arch Pathol Lab Med 1989;113:1151-4.
6. 6 Lifschitz Mercer B, Czernobilsky B, Dgani R, et al. Immunocytochemical study of an endometrial diffuse clear cell stromal sarcoma and other endometrial stromal sarcomas. Cancer 1987;59:1494-9.
7. 7 Norris HJ, Taylor HB. Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors. Cancer 1966;19:755-66.
8. 8 Evans HL. Endometrial stromal sarcoma and poorly differentiated endometrial sarcoma. Cancer 1982;50:2170-82.
9. 9 Chang KL, Crabtree GS, Lim Tan SK, et al. Primary uterine endometrial stromal neoplasms. Am J Surg Pathol 1990;14:415-38.
10. 10 De Fusco PA, Gaffey TA, Malkasian GD, et al. Endometrial stromal sarcoma: review of Mayo Clinic experience, 1945 1980. Gynecol Oncol 1989;35:8-14.
11. 11 Nordal RR, Kristensen GB, Kaern J, et al. The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. Gynecol Oncol 1996;62:254-9.
12. 12 Wolfson AH, Wolfson DJ, Sittler SY, et al. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcoma. Gynecol Oncol 1994;52:56-62.
13. 13 Nola M, Babic D, Ilic J, et al. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus. Cancer 1996;78:2543-50.
14. 14 Cheung AN, Tin VP, Ngan HY, et al. Interphase cytogenetic study of endometrial stromal sarcoma by chromosome in situ hybridization. Mod Pathol 1996;9:910-18.
15. 15 Dunton CJ, Kelsten ML, Brooks SE, et al. Low-grade stromal sarcoma: DNA flow cytometric analysis and estrogen progesterone receptor data. Gynecol Oncol 1990;37:268-75.
16. 16 Crawford HC, Matrisian LN. Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 1994-5;14:234-45.
17. 17 Aznavoorian S, Murphy AN, Stetler-Stevenson WG, et al. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71:1368-83.
18. 18 Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992;14:455-63.
19. 19 Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991;51:5054-9s.
20. 20 Tryggvason K, Hoyhtya M, Pyke C. Type IV collagenases in invasive tumors. Breast Cancer Res Treat 1993;24:209-18.
21. 21 Furcht LT, Skubitz APN, Fields GB. Tumor cell invasion, matrix metalloproteinases, and the dogma [editorial]. Lab Invest 1994;70:781-3.
22. 22 Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 1996;148:1345-50.
23. 23 Himelstein BP, Canete-Soler R, Bernhard EJ, et al. Metalloproteinases in tumor progression: The contribution of MMP-9. Invasion Metastasis 1994-5;14:246-58.
24. 24 Hua J, Muschel RJ. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res 1996;56:5279-84.
25. 25 Moses MA, Shing Y. Production of matrix metalloproteinase and a metalloproteinase inhibitor by swarm rat chondrosarcoma. Biochem Biophys Res Commun 1994;199:418-24.
26. 26 Sato H, Kida Y, Mai M, et al. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various tumor cells. Oncogene 1992;7:77-83.
27. 27 Okada Y, Tsuchiya H, Shimizu H, et al. Induction and stimulation of 92-kDa gelatinase/type IV collagenase production in osteosarcoma and fibrosarcoma cell lines by tumor necrosis factor alpha. Biochem Biophys Res Commun 1990;171:610-17.
28. 28 Rifas L, Fausto A, Scott MJ, et al. Expression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: differentiation is associated with repression of metalloproteinase biosynthesis. Endocrinology 1994;134:213-21.
29. 29 Kobayashi M, Hamada J, Li YQ, et al. A possible role of 92 kDa type IV collagenase in the extramedullary tumor formation in leukemia. Jpn J Cancer Res 1995;86:298-303.
30. 30 Benelli R, Adatia R, Ensoli B, et al. Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy. Oncol Res 1994;6:251-7.
31. 31 Sakamoto H, Nakayama Y, Ohtani K, et al. Pulmonary metastatic lesion of endolymphatic stromal myosis expresses metastasis-related genes but not invasion-related matrix type metalloproteinase. Cancer Lett 1997;112:245-9.
32. 32 Guesdon JL, Ternynck T, Avrameas S. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 1979;27:1131-9.
33. 33 Giorno RA. Comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. Diagn Immunol 1984;2:161-6.
34. 34 Nuovo GJ, MacConnel PB, Simsir A, et al. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res 1995; 55:267-75.
35. 35 Stack MS, Ellerbroek SM, Fishman DA. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int J Oncol 1998;12:569-76.
36. 36 Shima I, Sagaguri Y, Kusukawa J, et al. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma. A clinicopathologic study. Cancer 1992;70:2747-53.
37. 37 Brown PD, Bloxidge RE, Stuart NS, et al. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J Natl Cancer Inst 1993;85:574-8.
38. 38 Gilles C, Polette M, Seiki M, et al. Implication of collagen type I-induced membrane type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma. Lab Invest 1997;76:651-60.